Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29065860 | 0.79 | CA1 (0.66) | CA1MAPTLMNASMN1; SMN2NPSR1 | |
| SCHEMBL16375340 | 0.79 | CA1 (1.00) | CA1MAPTLMNASMN1; SMN2NPSR1 | |
| SCHEMBL28318413 | 0.78 | CA1 (0.76) | CA1MAPTLMNASMN1; SMN2NPSR1 | |
| SCHEMBL29065875 | 0.76 | CA1 (0.82) | CA1MAPTLMNASMN1; SMN2NPSR1 | |
| SCHEMBL10493317 | 0.74 | CA1 (0.55) | CA1MAPTLMNASMN1; SMN2NPSR1 | |
| SCHEMBL27929593 | 0.74 | CA1 (0.91) | CA1MAPTLMNASMN1; SMN2NPSR1 | |
| SCHEMBL30530181 | 0.74 | CA1 (0.78) | CA1MAPTLMNASMN1; SMN2NPSR1 | |
| SCHEMBL29065870 | 0.74 | CA1 (0.55) | CA1MAPTLMNASMN1; SMN2NPSR1 | |
| SCHEMBL28317423 | 0.73 | CA1 (0.82) | CA1MAPTLMNASMN1; SMN2NPSR1 | |
| SCHEMBL28015291 | 0.73 | CA1 (0.82) | CA1MAPTLMNASMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871668-B2 | Immobilized lewis acid catalysts coated with ionic liquids and use thereof | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-28 | — | — | US | disclosed |
| US-8871668-B2 | Immobilized lewis acid catalysts coated with ionic liquids and use thereof | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-28 | — | — | US | disclosed |
| US-8871668-B2 | Immobilized lewis acid catalysts coated with ionic liquids and use thereof | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-28 | — | — | US | disclosed |
| EP-1997555-B1 | IMMOBILIZED LEWIS ACID CATALYSTS COATED WITH IONIC LIQUIDS AND USE THEREOF | JAPAN SCIENCE & TECH AGENCY (JP) | 2013-02-27 | — | — | EP | disclosed |
| EP-1997555-B1 | IMMOBILIZED LEWIS ACID CATALYSTS COATED WITH IONIC LIQUIDS AND USE THEREOF | JAPAN SCIENCE & TECH AGENCY (JP) | 2013-02-27 | — | — | EP | disclosed |
| US-20090318729-A1 | IMMOBILIZED LEWIS ACID CATALYSTS COATED WITH IONIC LIQUIDS AND USE THEREOF | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318729-A1 | IMMOBILIZED LEWIS ACID CATALYSTS COATED WITH IONIC LIQUIDS AND USE THEREOF | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318729-A1 | IMMOBILIZED LEWIS ACID CATALYSTS COATED WITH IONIC LIQUIDS AND USE THEREOF | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-1997555-A1 | IMMOBILIZED LEWIS ACID CATALYSTS COATED WITH IONIC LIQUIDS AND USE THEREOF | Japan Science and Technology Agency (JP) | 2008-12-03 | — | — | EP | disclosed |
| EP-1997555-A1 | IMMOBILIZED LEWIS ACID CATALYSTS COATED WITH IONIC LIQUIDS AND USE THEREOF | Japan Science and Technology Agency (JP) | 2008-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318729-A1 | IMMOBILIZED LEWIS ACID CATALYSTS COATED WITH IONIC LIQUIDS AND USE THEREOF | SELL, LCT, LDHA | CA1 22/4885MAPT 3997/4885LMNA 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.